A Phase II Study of Subcutaneous Bevacizumab in Relapsed/Progressive Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 17 May 2017 Planned End Date changed from 1 Jun 2018 to 1 May 2018.
- 17 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.